NoticesDocument number 2026-20442New
Determination PRALIDOXIME CHLORIDE (Autoinjector) (Pralidoxime Chloride) Solution, 600 Milligrams/2 Milliliters (300 Milligrams/Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA, Agency, or we) has determined that PRALIDOXIME CHLORIDE (AUTOINJECTOR) (pralidoxime chloride) solution, 600 milligrams (mg)/2 milliliters (mL) (300 mg/mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for pralidoxime chloride solution, 600 mg/2 mL (300 mg/mL), if all other legal and regulatory requirements are met.
From Federal Register — all agencies (federalregister.gov). First seen Oct 10, 2026.
Details
- Published
- Oct 6, 2026Find in source ↗
- Agency
- Health and Human Services Department; Food and Drug AdministrationFind in source ↗
- Action
- Notice.Find in source ↗
- Dockets
- Docket No. FDA-2026-P-3632Find in source ↗
- Citation
- 91 FR 63562Find in source ↗
- Official PDF
- govinfo.gov
History
No changes since RuleWatch first read this rule on Oct 10, 2026.
Sign in to keep notes on this rule, private or shared with your team.